Wellington Management Co-Leads $215M Series B Financing of Metsera

Gunderson Dettmer represented client Wellington Management in co-leading the $215 million Series B financing of Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. The company is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Metsera will use the new capital to advance its portfolio of highly differentiated, clinical-stage, Nutrient-Stimulated Hormone (NuSH) analog peptides.

In the announcement of the transaction, Wellington Management’s Head of Biotech Private Investments Nilesh Kumar said, “We are excited to join a great investor syndicate to support Metsera’s differentiated portfolio of products for obesity.”

The Gunderson Dettmer deal team was led by Tim Ehrlich and included Tim Kulis, Annie Cho, Joel Diamond, Ross Ewing and Morgan Otway.

Companies
Wellington Management
Metsera